Presented at the ASHP Midyear 2019.
Based upon results from a military population study presented at ASHP 2019.
The pair were recognized for contributions to the association and industry.
Results at ASHP 2019 suggest potential for administration errors without proper guidance.
Biosimilar to Remicade
Allergan’s positive phase 3 trial results indicate a potential use for the CGRP receptor agonist.
Recent approval under new international Project Orbis.
Ultra-rare, potentially life-threatening genetic disease.
Hemoglobin S Polymerization inhibitor oral treatment.
Approved for patients 18 years of age and older